We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.085 | 3.93% | 2.25 | 2.20 | 2.30 | 2.50 | 2.25 | 2.30 | 1,046,356 | 09:03:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -2.02 | 7.67M |
TIDMIMM
RNS Number : 9563S
Immupharma PLC
29 December 2016
RNS : FOR IMMEDIATE RELEASE 29 DECEMBER 2016
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 7,421,555 Ordinary Shares which equates to a current position in the Company of 5.95% of the 124,638,362 total voting rights.
Full disclosure of the TR1 is shown below:
-Ends-
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Panmure, Gordon & Co., (NOMAD +44 (0) 20 & Broker) 7886 2500 Freddy Crossley, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Corporate Finance Rob Rees, John Howes, Corporate +44 (0)20 3861 Broking 6631 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) ----------------------------------------------------------------------------------- 1. Identity of the issuer or Immupharma plc the underlying issuer of existing shares to which voting rights are attached: (ii) ----------------------------------------------------------- ---------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ----------------------------------------------------------------------------------- An acquisition or disposal of voting rights x ------------------------------------------------------------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------------------- An event changing the breakdown of voting rights ------------------------------------------------------------------------------- Other (please specify): ---------------------------------------------------------- ------------------- 3. Full name of person(s) Lanstead Capital LP subject to the notification obligation: (iii) ----------------------------------------------------------- ---------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- ---------------------- 5. Date of the transaction 28 December 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- ---------------------- 6. Date on which issuer 28 December 2016 notified: ----------------------------------------------------------- ---------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 8%, 7%, 6% ----------------------------------------------------------- ---------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB0033711010 10,521,555 10,521,555 7,421,555 7,421,555 5.95% --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- N/A ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- N/A Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 7,421,555 5.95% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ---------------------------------------------------------------------------------------- N/A Proxy Voting: ---------------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ------------------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ------------------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ------------------------- 13. Additional information: ------------------------------------------------------------- ------------------------- 14. Contact name: Lisa De Vargas, Lanstead Partners Limited ------------------------------------------------------------- ------------------------- 15. Contact telephone number: +1 (801) 895-3700 ------------------------------------------------------------- -------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLBKLFLQLFEFBL
(END) Dow Jones Newswires
December 29, 2016 05:54 ET (10:54 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions